Subscribe
hailshadow-istockphoto-com
Hailshadow / iStockphoto.com
10 December 2018Big Pharma

Appeal filed against EPO sofosbuvir patent decision

Six organisations have appealed against the European Patent Office’s (EPO) decision to uphold a patent for a key hepatitis C drug.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
MSF critical of EPO decision to uphold Gilead’s hepatitis C patent
17 September 2018   The European Patent Office has upheld a patent covering Gilead’s hepatitis C medicine sofosbuvir, despite opposition from humanitarian organisation Médecins Sans Frontières.
Big Pharma
Medical tech leads 2020 innovation at the EPO
16 March 2021   Healthcare innovation led patenting activity in 2020 as COVID-19 fuelled a rise in applications, a report by the European Patent Office has revealed.


Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024

Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024
Unified Patent Court
Does the UPC offer a fresh take on patent validity?
5 September 2024

More on this story

Big Pharma
MSF critical of EPO decision to uphold Gilead’s hepatitis C patent
17 September 2018   The European Patent Office has upheld a patent covering Gilead’s hepatitis C medicine sofosbuvir, despite opposition from humanitarian organisation Médecins Sans Frontières.
Big Pharma
Medical tech leads 2020 innovation at the EPO
16 March 2021   Healthcare innovation led patenting activity in 2020 as COVID-19 fuelled a rise in applications, a report by the European Patent Office has revealed.

More on this story

Big Pharma
MSF critical of EPO decision to uphold Gilead’s hepatitis C patent
17 September 2018   The European Patent Office has upheld a patent covering Gilead’s hepatitis C medicine sofosbuvir, despite opposition from humanitarian organisation Médecins Sans Frontières.
Big Pharma
Medical tech leads 2020 innovation at the EPO
16 March 2021   Healthcare innovation led patenting activity in 2020 as COVID-19 fuelled a rise in applications, a report by the European Patent Office has revealed.

More features

GSK triumphs in EPO appeal, revoking Pfizer patent
‘We took Ravgen head-on’: How we won zero-damages and others didn't
Kathi Vidal to leave USPTO ahead of incoming Trump administration
Herbert Smith Freehills and Kramer Levin in $2bn merger talks
Teva fights for re-listing of inhaler patents at US appeals court
CRISPR patents revoked following Nobel Prize winners’ withdrawal
White & Case hires experienced litigator from A&O Shearman
President Trump 2.0: Five major areas to watch